Daewoong Pharmaceutical Co., Ltd. (KOSPI: 003690) is a leading South Korean pharmaceutical company headquartered in Seongnam, South Korea. Founded in 1932, Daewoong has evolved from a traditional pharmaceutical manufacturer into a diversified healthcare company with significant focus on advanced therapies, including cell therapy, gene therapy, and innovative small molecules for neurodegenerative diseases. The company represents one of Korea's largest domestic pharmaceutical players and has been actively expanding its global footprint through strategic partnerships and international market entry[1].
| Attribute | Details |
|---|---|
| Company Name | Daewoong Pharmaceutical Co., Ltd. |
| Headquarters | Seongnam, Gyeonggi-do, South Korea |
| Founded | 1932 |
| CEO | Lee Seung-ho |
| Stock Exchange | KOSPI |
| Ticker | 003690 |
| Revenue | ~$1.5B USD (2023) |
| Employees | ~3,000 |
| Focus | Pharmaceuticals, cell therapy, global expansion |
| Year | Milestone |
|---|---|
| 1932 | Founded as Korean Pharmaceutical Company |
| 1970s | Major expansion of generic drug portfolio |
| 2000 | Entered biopharmaceuticals business |
| 2010 | Established cell therapy R&D center |
| 2015 | First overseas acquisition (US) |
| 2020 | Expanded into gene therapy |
| 2022 | Major partnership for Parkinson's cell therapy |
| 2023 | Global clinical trials for DW-5905 |
Daewoong's core pharmaceutical business encompasses:
The biotechnology arm focuses on:
International operations include:
| Drug | Mechanism | Stage | Notes |
|---|---|---|---|
| DW-5905 | Dopamine D1/D2 receptor agonist | Phase 2 | Oral, long-acting formulation |
| DW-6302 | Cell therapy (mesenchymal stem cells) | Preclinical | IND-enabling for 2025 |
| DW-7101 | MAO-B inhibitor | Phase 1 | Novel formulation |
DW-5905 is Daewoong's lead Parkinson's disease program, designed as a新一代 dopamine receptor agonist with improved receptor selectivity and longer duration of action compared to existing treatments. The compound aims to provide better motor symptom control while reducing dyskinesia side effects[2].
| Drug | Mechanism | Stage | Notes |
|---|---|---|---|
| DW-7801 | BACE1 inhibitor | Discovery | Program halted due to safety concerns |
| DW-8201 | Anti-amyloid monoclonal antibody | Preclinical | Partnership with US biotech |
| DW-8501 | Tau aggregation inhibitor | Discovery | Early research |
| Drug | Indication | Stage |
|---|---|---|
| DW-9101 | ALS | Discovery |
| DW-9202 | Multiple sclerosis | Phase 1 |
Daewoong Pharmaceutical's neuroscience division maintains focus on several key areas:
Daewoong has invested significantly in stem cell technology for neurodegenerative diseases:
| Product | Indication | Notes |
|---|---|---|
| Nexlet® | Parkinson's disease (Levodopa/Carbidopa) | Leading domestic brand |
| Dexedrine® | ADHD | Market leader in Korea |
| Cureith® | Antidepressant | SNRI class |
| Daewoong products | Various | Broad CNS portfolio |
Daewoong holds a significant share of the Korean pharmaceutical market, particularly in:
Daewoong has pursued international expansion through multiple pathways:
| Partner | Focus | Type |
|---|---|---|
| Unknown US biotech | Anti-amyloid antibody | Co-development |
| Japanese pharma | Parkinson's cell therapy | Licensing |
| European company | Generic CNS drugs | Distribution |
Daewoong has pursued acquisitions to accelerate its pipeline:
| Metric | Value (2023) |
|---|---|
| Revenue | ~$1.5B USD |
| Operating Profit | ~$150M USD |
| R&D Investment | ~$200M (~13% of revenue) |
| Market Cap | ~$2B USD |
| KOSPI | 003690 |
In the Korean market, Daewoong competes with:
Globally, Daewoong positions itself as a partner for Asian market access and a competitor in the cell therapy space.